Additional Study Information: The purpose of this study is to determine the safety and effectiveness of two drugs, either rituximab or tocilizumab, in patients who develop side effects while on treatment with immunotherapy requiring prolonged steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Both rituximab and tocilizumab have been given to patients with autoimmune diseases (diseases where the immune system is activated against normal organs). Immune-related side effects appear to closely mirror these autoimmune conditions. Cancers include: Bladder cancer, esophageal cancer, colon/rectal cancer, cervical cancer, kidney/adrenal cancer, lung cancer, head/neck cancers, liver cancer, skin cancer, sarcomas, pancreatic cancer, stomach cancer, and prostate cancer.